Condition: Solid Tumor · Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic solid tumor.
This description comes directly from the study's public registry record.
Jianhua Chen, Doctor · +86 17321168230 · jianhuachen15@163.com
Always discuss trial participation with your own doctor first.
| RenJi Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanghai General Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05831033